ME-015 (Suplatast Tosilate)
Chronic cough in Idiopathic Pulmonary Fibrosis (IPF)
Phase 2Active
Key Facts
Indication
Chronic cough in Idiopathic Pulmonary Fibrosis (IPF)
Phase
Phase 2
Status
Active
Company
About Melius Pharma
Melius Pharma is a private, clinical-stage biotech based in Stockholm, Sweden, leveraging a low-risk development model. The company's core asset is ME-015 (suplatast tosilate), a drug with over 25 years of real-world safety data in Japan, now in Phase 2 for chronic cough in IPF. Melius's strategy involves sourcing late-stage assets with proven safety profiles and developing them in high-value, niche indications to reduce clinical risk and enhance partnering appeal. The company is backed by seasoned Swedish life science investors and is targeting topline Phase 2 readouts in 2025.
View full company profileTherapeutic Areas
Other Chronic cough in Idiopathic Pulmonary Fibrosis (IPF) Drugs
| Drug | Company | Phase |
|---|---|---|
| Haduvio (oral nalbuphine ER) | Trevi Therapeutics | Phase 2b |